C. Diff News and Research

RSS

Rebiotix's RBX2660 receives FDA Breakthrough Therapy designation for treatment of recurrent C diff infection

Rebiotix Inc. today announced that U.S. Food and Drug Administration has designated its lead Microbiota Restoration Therapy (MRT) RBX2660 as a Breakthrough Therapy for the treatment of recurrent Clostridium difficile (C diff) infection, a challenging to treat gastrointestinal (GI) infection that causes 29,000 deaths in the U.S. annually.

12 Oct 2015

UV robots help reduce rates of C. diff transmission among cancer inpatients

Robots are capable of all sorts of tasks to help better treat cancer: They connect oncologists to patients remotely, make incisions, staple them shut, deliver "nano" therapies--and they clean rooms. New research from Penn Medicine infection control specialists found that ultraviolet (UV) robots helped reduce the rates transmission of the common bacterial infection known as Clostridium difficile among cancer inpatients - mostly blood cancer patients, a group more vulnerable to hospital-acquired infections - by 25 percent. The interventions also saved about $150,000 in annual direct medical costs.

12 Oct 2015

Mercy open new Endoscopy Suite to promote and practice gastrointestinal health

Mercy Medical Center has announced the opening of a new, state-of-the-art Endoscopy Suite to promote and practice gastrointestinal health. The unique, high-tech suite is located on the 2nd floor of Mercy's Mary Catherine Bunting Center at 345 St. Paul Place. Bunting Endoscopy will be under the direction of Dr. Paul J. Thuluvath, Medical Director of The Melissa L. Posner Institute for Digestive Health & Liver Disease at Mercy.

6 Oct 2015

BD Life Sciences announces FDA clearance for BD MAX Enteric Parasite Panel

BD Life Sciences, a segment of global medical technology company BD (Becton, Dickinson and Company), today announced the availability of the U.S. Food and Drug Administration cleared BD MAX Enteric Parasite Panel for use on the BD MAX System.

From BD (Becton, Dickinson and Company) 24 Sep 2015

Probiotics show no benefit in preventing gastrointestinal colonization with drug-resistant microbes in ICU patients

Compared with routine medical care, probiotics administered to critically ill patients in intensive care units showed no benefit in preventing the colonization of drug-resistant microbes in the intestinal tract, according to new research at Washington University School of Medicine in St. Louis.

28 Aug 2015

Major gaps found in existing evidence for best practices for cleaning hospital room surfaces to prevent HAIs

Tray tables, bed rails, light switches, and toilets: All are common vectors for swapping germs between patients and health care workers. While a new systematic overview in this week's Annals of Internal Medicine points to several promising cleaning tactics of these "high-touch surfaces," there's a lack of evidence as to which is the most effective at reducing healthcare-associated infections (HAIs).

11 Aug 2015

Coordinated, two-part approach could help reduce hospital-acquired infections

By coordinating with state health departments and communicating with each other about patients with C. difficile and antibiotic-resistant infections, hospitals, long-term acute-care facilities and nursing homes could reduce the number of such hospital-acquired infections (HAIs) by an estimated 619,000 cases in the next five years, a new Centers for Disease Control 9 (CDC)-led report has found.

5 Aug 2015

Hospitals can make patients sick, reveals Consumer Reports

Hospitals are thought to be sterile, safe environments where sick people get better, not sicker. But that's not always the case according to a new investigation by Consumer Reports into hospital-acquired infections.

29 Jul 2015

Mix of bacteria living in guts may band together to ward off dangerous infections

Like a collection of ragtag villagers fighting off an invading army, the mix of bacteria that live in our guts may band together to keep dangerous infections from taking hold, new research suggests.

24 Jul 2015

UTHealth scientist receives $1.9 million from NIH to develop non-antibiotic treatment for C. diff infections

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the National Institutes of Health to develop a non-antibiotic treatment for Clostridium difficile (C. diff) infections.

10 Jul 2015

NHS Scotland's Golden Jubilee National Hospital deploys MicroStrategy platforms to improve patient care, enhance operations

MicroStrategy® Incorporated, a leading worldwide provider of enterprise software platforms, today announced that NHS Scotland's Golden Jubilee National Hospital has deployed the MicroStrategy Analytics Platform™ and MicroStrategy Mobile™ to monitor, report, and analyze over 200 quality indicators consisting of patient care, staffing, and performance metrics.

24 Jun 2015

Fecal transplantation cures C. diff infection, eliminates multi-drug resistant pathogens

A fecal microbiota transplant (FMT) not only cured a case of Clostridium difficile (C. diff) infection in a 66 year old man; it eliminated populations of multi-drug resistant organisms both in the patient's gastrointestinal tract, and several other body sites.

7 May 2015

U-M study: Nearly half of American hospitals not taking key steps to prevent C. diff infections

Nearly half of American hospitals aren't taking key steps to prevent a kind of gut infection that kills nearly 30,000 people annually and sickens hundreds of thousands more - despite strong evidence that such steps work, according to a new study.

25 Apr 2015

Seal Shield's new Airocide DS air purifier may help eliminate 'Super Bugs' in hospitals

Seal Shield LLC (Jacksonville, FL), today announced the new Airocide DS air purifier. The Airocide DS is a table top or bed side air purification product that uses a unique photocatalytic biocide reactor to eliminate viral, fungal and bacterial pathogens from the air. Developed by NASA, Airocide converts dangerous bacteria, virus and destructive VOC's into harmless water vapor without producing ozone or other harmful byproducts.

9 Apr 2015

Study examines efficacy of continuous UV-C robots versus pulsed xenon in preventing infection

The efficacy of continuous UV-C disinfection robots versus pulsed xenon (PU-UX) was highlighted in a recently published study of ultraviolet (UV) light disinfection systems by an influential infection prevention research team, including Curtis Donskey, M.D.

1 Apr 2015

C. Diff News and Research

Rebiotix's RBX2660 receives FDA Breakthrough Therapy designation for treatment of recurrent C diff infection

UV robots help reduce rates of C. diff transmission among cancer inpatients

Mercy open new Endoscopy Suite to promote and practice gastrointestinal health

BD Life Sciences announces FDA clearance for BD MAX Enteric Parasite Panel

Probiotics show no benefit in preventing gastrointestinal colonization with drug-resistant microbes in ICU patients

Major gaps found in existing evidence for best practices for cleaning hospital room surfaces to prevent HAIs

Coordinated, two-part approach could help reduce hospital-acquired infections

Hospitals can make patients sick, reveals Consumer Reports

Mix of bacteria living in guts may band together to ward off dangerous infections

UTHealth scientist receives $1.9 million from NIH to develop non-antibiotic treatment for C. diff infections

NHS Scotland's Golden Jubilee National Hospital deploys MicroStrategy platforms to improve patient care, enhance operations

Fecal transplantation cures C. diff infection, eliminates multi-drug resistant pathogens

U-M study: Nearly half of American hospitals not taking key steps to prevent C. diff infections

Seal Shield's new Airocide DS air purifier may help eliminate 'Super Bugs' in hospitals

Study examines efficacy of continuous UV-C robots versus pulsed xenon in preventing infection

Aggressive campaign to cut unnecessary use of antibiotics helps reduce drug-resistant bacteria

Deadly C. difficile affected almost half a million in the U.S over one year

Great Basin Scientific begins clinical trial for Shiga toxin-producing E. coli diagnostic test

Great Basin Scientific seeks FDA approval for Group B Strep assay

TRU-D SmartUVC’s Ebola-killing UVC automated disinfection robot to be showcased at IDWeek 2014

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News